Rocket Pharmaceuticals Files 8-K on Financials
Ticker: RCKTW · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | 8-K |
| Filed Date | Aug 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, company-update
TL;DR
Rocket Pharma dropped an 8-K detailing financials – check it out.
AI Summary
Rocket Pharmaceuticals, Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 9 Cedarbrook Drive, Cranbury, NJ 08512. The company was formerly known as Inotek Pharmaceuticals Corp.
Why It Matters
This 8-K filing provides investors with crucial updates on Rocket Pharmaceuticals' financial performance and operational status, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Rocket Pharmaceuticals, Inc. (company) — Registrant
- Inotek Pharmaceuticals Corp (company) — Former company name
- August 5, 2024 (date) — Date of report
- 9 Cedarbrook Drive, Cranbury, NJ 08512 (address) — Principal executive offices
- 350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY 10118 (address) — Business address
FAQ
What is the primary purpose of this Form 8-K filing?
The primary purpose of this Form 8-K filing is to report on Rocket Pharmaceuticals, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the report filed and what is the date of the earliest event reported?
The report was filed on August 5, 2024, and the date of the earliest event reported is also August 5, 2024.
What is Rocket Pharmaceuticals, Inc.'s principal executive office address?
Rocket Pharmaceuticals, Inc.'s principal executive office is located at 9 Cedarbrook Drive, Cranbury, NJ 08512.
Has Rocket Pharmaceuticals, Inc. operated under any former names?
Yes, Rocket Pharmaceuticals, Inc. was formerly known as Inotek Pharmaceuticals Corp, with a date of name change on February 26, 2004.
What is the company's SIC code and state of incorporation?
The company's Standard Industrial Classification (SIC) code is 2834 (Pharmaceutical Preparations), and it is incorporated in Delaware.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-08-05 16:17:36
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
Filing Documents
- ef20033571_8k.htm (8-K) — 29KB
- ef20033571_ex99-1.htm (EX-99.1) — 97KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-24-035756.txt ( ) — 275KB
- rckt-20240805.xsd (EX-101.SCH) — 4KB
- rckt-20240805_lab.xml (EX-101.LAB) — 21KB
- rckt-20240805_pre.xml (EX-101.PRE) — 16KB
- ef20033571_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On August 5, 2024, Rocket Pharmaceuticals, Inc. (the "Company") announced certain preliminary financial information for the quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated August 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: August 5, 2024 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP